

Appendix 3Y

Change of Director's Interest Notice

Name of entity	Incannex Healthcare Limited
ABN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Sudhanshu AGARWAL
Date of last notice	01 July 2021

Part 1 - Change of director's relevant interests in securities

Direct or indirect interest	Direct and Indirect
Nature of indirect interest	Dr Agarwal is a shareholder, CEO and director of Cannvalate Pty Ltd ("Cannvalate"). 'Indirect' positions disclosed in this Appendix 3Y are held by Cannvalate - Dr Agarwal does not have sole discretion over the acquisition or disposal of these positions.
Date of change	06 September 2021
No. and class of securities held prior to change	Direct 34,303,593 fully paid ordinary shares ("IHL") 2,000,000 unlisted performance rights 200,000,000 \$0.20 unlisted options expiry 30-Sep-21 Indirect 32,000,000 fully paid ordinary shares ("IHL")
Number and class of securities acquired	20,000,000
Number and class of securities disposed	Nil
Value/Consideration	\$ 4,000,000.00
No. of securities held after change	Direct 34,303,593 fully paid ordinary shares ("IHL") 180,000,000 \$0.20 unlisted options expiry 30-Sep-21 Indirect 32,000,000 fully paid ordinary shares ("IHL")
Nature of change	Conversion of \$0.20 unlisted options expiry 30-Sep-21

Part 2 – Change of director's interests in contracts – no change

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

Appendix 3Y

Change of Director's Interest Notice

Name of entity	Incannex Healthcare Limited
ACN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Joel LATHAM
Date of last notice	01 July 2021

Part 1 - Change of director's relevant interests in securities

Direct or indirect interest	Direct
Date of change	06 September 2021
No. and class of securities held prior to change	<ul style="list-style-type: none"> • 15,396,669 IHL ordinary shares • 200,000 unlisted \$0.08 Options expiry 30-Sep-21 • 2,551,745 IHL ordinary shares (voluntary escrow) • 1,500,000 unlisted \$0.05 options – expiry 30-Jun-2025 • 750,000 unlisted \$0.05 options – expiry 30-Jun-2026 • 750,000 unlisted \$0.05 options – expiry 30-Jun-2026 (ESC) • 1,500,000 unlisted \$0.05 options – expiry 30-Jun-2027 (ESC)
Number and class of securities acquired	<ul style="list-style-type: none"> • 200,000 IHL ordinary shares
Number and class of securities disposed	<ul style="list-style-type: none"> • Nil
Value/Consideration	\$ 16,000.00
No. of securities held after change	<ul style="list-style-type: none"> • 15,596,669 IHL ordinary shares • 2,551,745 IHL ordinary shares (voluntary escrow) • 1,500,000 unlisted \$0.05 options – expiry 30-Jun-2025 • 750,000 unlisted \$0.05 options – expiry 30-Jun-2026 • 750,000 unlisted \$0.05 options – expiry 30-Jun-2026 (ESC) • 1,500,000 unlisted \$0.05 options – expiry 30-Jun-2027 (ESC)
Nature of change	<ul style="list-style-type: none"> • Conversion of unlisted \$0.08 Options expiry 30-Sep-21

Part 2 – Change of director's interests in contracts

Not Applicable

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a